MDT-AP-1214
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 134.04
- os_event
- false
- age_years
- 10
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.306525046
- umap2_2d
- 5.868139419
- umap1_3d
- 2.634649022
- umap2_3d
- -1.532731478
- umap3_3d
- -4.330164217
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.420
- PROTEIN_SECRETION+0.400
- MITOTIC_SPINDLE+0.330
- HEME_METABOLISM+0.310
- OXIDATIVE_PHOSPHORYLATION+0.280
- G2M_CHECKPOINT+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- FATTY_ACID_METABOLISM+0.240
- PI3K_AKT_MTOR_SIGNALING+0.240
- E2F_TARGETS+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ALLOGRAFT_REJECTION-0.410
- INFLAMMATORY_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
- KRAS_SIGNALING_UP-0.360
- COAGULATION-0.320
- PANCREAS_BETA_CELLS-0.320
- ANGIOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290941 | — | — | 0.903 |
| 2 | MDT-AP-1122 | Med | Medulloblastoma | 0.888 |
| 3 | MDT-AP-0553 | Med | Medulloblastoma | 0.880 |
| 4 | SAMN03290953 | — | — | 0.878 |
| 5 | MDT-AP-1366 | Med | Medulloblastoma | 0.870 |
| 6 | BS_4CP4T22V | Med | Medulloblastoma | 0.870 |
| 7 | BS_GNV89A5P | Med | Medulloblastoma | 0.868 |
| 8 | SRR23303743 | — | — | 0.854 |
| 9 | MDT-AP-1258 | Med | Medulloblastoma | 0.854 |
| 10 | BS_BSV07M7Z | Med | Medulloblastoma | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.310 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |